Palonosetron in Pediatric Patients: A Single-center, Retrospective Evaluation of Policy and Clinical Practice Guideline Discordance

Overview

Journal J Oncol Pharm Pract

Publisher Sage Publications

Specialties Oncology
Pharmacy

Date 2024 Mar 1

PMID 38425048

Authors

Meredith Ames

Priya Patel

L Lee Dupuis

Alicia Koo

Affiliations

Soon will be listed here.

Abstract

IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG.MethodsA retrospective review of the health records of patients who received palonosetron between 1 July 2019 and 30 June 2020 was undertaken. Details of palonosetron use, antiemetic regimen and the date and time of each vomit during the acute and delayed phases were collected for each chemotherapy block where palonosetron was given. Discordance with the institutional policy and the source CPG was determined by assessing the indication for palonosetron and the dose. In the subset of chemotherapy blocks where information regarding vomiting episodes was available, the extent of acute phase chemotherapy-induced vomiting (CIV) control was reported.ResultsFour hundred thirty-eight chemotherapy blocks, representing 122 patients (mean age 9 years), receiving 595 palonosetron doses were included. Palonosetron use was discordant with institutional policy during most (72%; 314/438) of the chemotherapy blocks analyzed. However, palonosetron use was concordant with the source CPG during most chemotherapy blocks (74%; 326/438). Complete CIV control during the acute phase was observed in 66% (195/295) of chemotherapy blocks where palonosetron was given, irrespective of concomitant antiemetics administered.ConclusionThe majority of palonosetron use at our institution was discordant with institutional policy, but concordant with the source CPG. Our institutional policy has since been updated to be more aligned with the source CPG.

References

Tan J, Wang S, Liang X, Li C, Zhang J, Zhao Z . Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy. Pediatr Blood Cancer. 2017; 65(2). DOI: 10.1002/pbc.26815. View

Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D . The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012; 23(8):1986-1992. DOI: 10.1093/annonc/mds021. View

Patel P, Paw Cho Sing E, Dupuis L . Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis. Expert Opin Drug Saf. 2019; 18(2):97-110. DOI: 10.1080/14740338.2019.1568988. View

Patel P, Robinson P, Cohen M, Devine K, Gibson P, Holdsworth M . Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. Pediatr Blood Cancer. 2022; 69(12):e30001. DOI: 10.1002/pbc.30001. View

Flank J, Robinson P, Holdsworth M, Phillips R, Portwine C, Gibson P . Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer. 2016; 63(7):1144-51. DOI: 10.1002/pbc.25955. View

Sepulveda-Vildosola A, Betanzos-Cabrera Y, Lastiri G, Rivera-Marquez H, Villasis-Keever M, Del Angel V . Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res. 2008; 39(6):601-6. DOI: 10.1016/j.arcmed.2008.04.007. View

Jordan K, Chan A, Gralla R, Jahn F, Rapoport B, Warr D . 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2016; 25(1):271-275. DOI: 10.1007/s00520-016-3332-x. View

De Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G . Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. Support Care Cancer. 2018; 26(12):4021-4029. DOI: 10.1007/s00520-018-4259-1. View

Kovacs G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E . Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority.... Lancet Oncol. 2016; 17(3):332-344. DOI: 10.1016/S1470-2045(15)00520-3. View

10.

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. DOI: 10.1200/JCO.2017.74.4789. View

11.

Aapro M, Caprariu Z, Chilingirov P, Chrapava M, Curca R, Gales L . Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO). Eur J Cancer. 2022; 166:126-133. DOI: 10.1016/j.ejca.2022.01.028. View

12.

Gilmore J, Peacock N, Gu A, Szabo S, Rammage M, Sharpe J . Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2013; 10(1):68-74. DOI: 10.1200/JOP.2012.000816. View

13.

Dupuis L, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P . Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011; 57(2):191-8. PMC: 6554029. DOI: 10.1002/pbc.23114. View

14.

Dupuis L, Boodhan S, Holdsworth M, Robinson P, Hain R, Portwine C . Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013; 60(7):1073-82. DOI: 10.1002/pbc.24508. View

15.

Wright J, Neugut A, Ananth C, Lewin S, Wilde E, Lu Y . Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med. 2013; 173(7):559-68. PMC: 3674413. DOI: 10.1001/jamainternmed.2013.2921. View

16.

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020; 38(24):2782-2797. DOI: 10.1200/JCO.20.01296. View

17.

Patel P, Robinson P, Thackray J, Flank J, Holdsworth M, Gibson P . Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer. 2017; 64(10). DOI: 10.1002/pbc.26542. View

18.

Patil V, Noronha V, Joshi A, Ramaswamy A, Gupta S, Sahu A . Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. J Oncol Pract. 2017; 13(6):e574-e581. DOI: 10.1200/JOP.2016.019448. View

19.

Sugalski A, Lo T, Beauchemin M, Grimes A, Robinson P, Walsh A . Facilitators and barriers to clinical practice guideline-consistent supportive care at pediatric oncology institutions: a Children's Oncology Group study. Implement Sci Commun. 2021; 2(1):106. PMC: 8447588. DOI: 10.1186/s43058-021-00200-2. View